Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
VAMAS6
MCID: VTL009
MIFTS: 42

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VAMAS6)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 57 13
Generalized Vitiligo 74 72
Vitiligo 74 72
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 72
Vamas6 57
Vtlg 74

Characteristics:

OMIM:

57
Inheritance:
? epistatically interacting multiple autosomal recessive


HPO:

32
vitiligo-associated multiple autoimmune disease susceptibility 6:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 193200
MeSH 44 D014820
UMLS 72 C0042900 C1304470 C1847835
Sources

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
UniProtKB/Swiss-Prot : 74 Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6, also known as generalized vitiligo, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and deafness, congenital, with vitiligo and achalasia, and has symptoms including pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22). The drugs Pimecrolimus and mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and t cells, and related phenotypes are vitiligo and nevus

More information from OMIM: 193200
Sources

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 610)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 13.2
2 deafness, congenital, with vitiligo and achalasia 12.6
3 alopecia universalis onychodystrophy vitiligo 12.4
4 obsolete: vitiligo-associated autoimmune disease 12.3
5 vitiligo, progressive, with mental retardation and urethral duplication 12.3
6 spastic paraplegia 23, autosomal recessive 12.2
7 autoimmune disease 1 12.1
8 alopecia areata 11.8
9 alezzandrini syndrome 11.7
10 autoimmune disease 2 11.6
11 autoimmune disease 3 11.6
12 autoimmune disease 4 11.6
13 schrander-stumpel theunissen hulsmans syndrome 11.6
14 vogt-koyanagi-harada disease 11.6
15 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.6
16 autoimmune polyglandular syndrome type 3 11.6
17 halo nevi 11.5
18 hypoadrenocorticism, familial 11.4
19 hemifacial atrophy, progressive 11.4
20 autoimmune atrophic gastritis 11.4
21 stiff-person syndrome 11.3
22 hereditary spastic paraplegia 23 11.2
23 ermine phenotype 11.1
24 nijmegen breakage syndrome 11.1
25 lelis syndrome 11.1
26 t-cell receptor-alpha/beta deficiency 11.1
27 hypopigmentation of eyelid 11.1
28 combined immunodeficiency with skin granulomas 11.1
29 gemignani syndrome 11.1
30 pigmentation anomaly of the skin 11.1
31 autoimmune disease 10.9
32 skin disease 10.7
33 alopecia 10.7
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
35 psoriasis 10.7
36 pustulosis of palm and sole 10.7
37 melanoma 10.6
38 thyroiditis 10.6
39 hypothyroidism 10.6
40 dowling-degos disease 1 10.5
41 dermatitis 10.5
42 dermatitis, atopic 10.5
43 hashimoto thyroiditis 10.4
44 skin carcinoma 10.4
45 lichen planus 10.4
46 thyroid gland disease 10.4
47 pernicious anemia 10.4
48 graves' disease 10.4
49 uveitis 10.3
50 systemic scleroderma 10.3

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6
Sources

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

32
# Description HPO Frequency HPO Source Accession
1 vitiligo 32 HP:0001045
2 nevus 32 HP:0003764

Symptoms via clinical synopsis from OMIM:

57
Skin:
vitiligo
halo nevi

Misc:
onset after birth
no predilection for ventral skin

Clinical features from OMIM:

193200

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:


pruritus, exanthema
Sources

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
2
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
3
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
4
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
5 Amotosalen Phase 4
6 Ficusin Phase 4
7 Furocoumarins Phase 4
8 Neurotransmitter Agents Phase 4
9 abobotulinumtoxinA Phase 4
10 Cholinergic Agents Phase 4
11 Neuromuscular Agents Phase 4
12 Acetylcholine Release Inhibitors Phase 4
13 Botulinum Toxins Phase 4
14 Botulinum Toxins, Type A Phase 4
15
Zinc Approved, Investigational Phase 3 7440-66-6 32051
16
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
17
Latanoprost Approved, Investigational Phase 2, Phase 3 130209-82-4 5282380 5311221
18
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
19
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
20 Adjuvants, Immunologic Phase 3
21 Viscosupplements Phase 3
22 Micronutrients Phase 3
23 Trace Elements Phase 3
24 Nutrients Phase 3
25 Dermatologic Agents Phase 3
26 insulin Phase 3
27 Insulin, Globin Zinc Phase 3
28 Astringents Phase 3
29 Janus Kinase Inhibitors Phase 3
30 Hormones Phase 2, Phase 3
31 Immunologic Factors Phase 2, Phase 3
32 Immunosuppressive Agents Phase 2, Phase 3
33 Calcineurin Inhibitors Phase 2, Phase 3
34 Hormone Antagonists Phase 2, Phase 3
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
36 Triamcinolone hexacetonide Phase 2, Phase 3
37 triamcinolone acetonide Phase 2, Phase 3
38 Triamcinolone diacetate Phase 2, Phase 3
39 glucocorticoids Phase 2, Phase 3
40
Etanercept Approved, Investigational Phase 2 185243-69-0
41
Simvastatin Approved Phase 1, Phase 2 79902-63-9 54454
42
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
43
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
44
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
45
Pembrolizumab Approved Phase 2 1374853-91-4
46
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
47
Durvalumab Approved, Investigational Phase 2 1428935-60-7
48
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
49
Afamelanotide Experimental, Investigational Phase 2 75921-69-6
50
Bavituximab Investigational Phase 2 648904-28-3

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
2 Comparison the Efficacy and Safety of 0.1% Tacrolimus Ointment With 0.1% Mometasone Furoate Cream in the Treatment of Adult Vitiligo: A Single Blinded Pilot Study Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
3 Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize Unknown status NCT01377077 Phase 4
4 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study Unknown status NCT01640678 Phase 4
5 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
6 Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo Completed NCT01732965 Phase 4
7 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
8 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation Completed NCT02458417 Phase 4
9 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Recruiting NCT03199664 Phase 4
10 Bimatoprost 0.03% Solution, NB-UVB and Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Not yet recruiting NCT03487042 Phase 4 Bimatoprost 0.03% ophthalmic solution
11 Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
12 A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Unknown status NCT02156427 Phase 3
13 Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
14 Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients Unknown status NCT00525395 Phase 3
15 Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo Completed NCT00830713 Phase 3
16 Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo Completed NCT00696358 Phase 3
17 Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study Completed NCT00807690 Phase 3 Tacrolimus ointment
18 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
19 Efficacy and Tolerance of Transplantation of Harvested Epidermal Cells and Narrow-Band UVB in Vitiligo Completed NCT01629979 Phase 2, Phase 3
20 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3 Bras B : The group control
21 Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts, A Randomized Clinical Trial Recruiting NCT03158168 Phase 3 Candida Antigen;Zinc Sulfate
22 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Not yet recruiting NCT04057573 Phase 3 Ruxolitinib cream;Vehicle
23 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Not yet recruiting NCT04052425 Phase 3 Ruxolitinib cream;Vehicle
24 Effectiveness of Microneedling and Topical Latanoprost in Treatment of Acrofacial Vitiligo Not yet recruiting NCT03611348 Phase 2, Phase 3 Latanoprost
25 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Terminated NCT02191748 Phase 2, Phase 3 Triamcinolone
26 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control, Randomized and Double Blind Study Terminated NCT01841008 Phase 2, Phase 3 Protopic;Placebo : Diprobase
27 Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3 Group 01;Group 02
28 Comparative Study of the Use of Trypsin Versus Dispase in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
29 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
30 Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial Unknown status NCT01787708 Phase 2
31 Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
32 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
33 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial Unknown status NCT01792245 Phase 2
34 A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo Completed NCT01517893 Phase 2 Simvastatin;Placebo
35 Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Completed NCT00372307 Phase 2 Application of pimecrolimus
36 Pilot, Investigator-Initiated, Proof-of-Concept, Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo Completed NCT00134368 Phase 2 Etanercept
37 A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2 Afamelanotide
38 Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
39 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2
40 Phase I-II, Randomized, Intraindividually Placebo Controlled Clinical Trial, to Evaluate the Efficacy of Autologous Melanocyte Transplantion on Amniotic Membrane as a Substrate for Patients With Stable Vitiligo. Completed NCT01701648 Phase 1, Phase 2
41 Atorvastatin in Active Vitiligo: a Bicentric Prospective Randomized Trial Completed NCT02432534 Phase 2 Atorvastatin
42 The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo (EVRAAS) Recruiting NCT03247400 Phase 1, Phase 2 1% simvastatin-acid sodium salt ointment;1% atorvastatin calcium salt ointment
43 Effectivness of Topical Tacrolimus 0.03% Monotherapy in Patients With Vitiligo: Arandomized Controlled Trial Recruiting NCT03358082 Phase 1, Phase 2 Tacrolimus 0.03% Ointment;Hydrocortisone Acetate 1% Ointment
44 A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO Recruiting NCT03715829 Phase 2 PF-06651600;PF-06651600;PF-06651600;PF-06651600;PF-06651600;placebo;PF06700841
45 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
46 A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT03519997 Phase 2 Pembrolizumab;Bavituximab
47 A Randomized, Double-Blind, Dose-Ranging Study of Ruxolitinib Phosphate Cream in Subjects With Vitiligo Active, not recruiting NCT03099304 Phase 2 Ruxolitinib cream;Vehicle cream
48 An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo Active, not recruiting NCT03468855 Phase 2 ATI-50002 topical solution
49 A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Active, not recruiting NCT03123016 Phase 2 Apremilast
50 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO Active, not recruiting NCT03036995 Phase 2 Apremilast

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Methoxsalen
monobenzone
Trioxsalen
Sources

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
Sources

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

41
Skin, Thyroid, T Cells, Testes, Liver, Bone, Eye
Sources

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

(show top 50) (show all 6499)
# Title Authors PMID Year
1
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. 38 8
20526339 2010
2
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. 38 8
20410501 2010
3
Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. 38 8
11941482 2002
4
Treatment outcome and persistence of repigmentation from narrow-band ultraviolet B phototherapy in vitiligo. 38
30474443 2019
5
Comparison of prognosis in centrofacial, panfacial and hairline vitiligo: a prospective cohort study. 38
30640572 2019
6
Evaluation of using fractional CO2 laser plus NB-UVB versus NB-UVB alone in inducing marginal repigmentation of vitiligo lesions. 38
30592235 2019
7
JAK-inhibitors in dermatology: current evidence and future applications. 38
30433838 2019
8
Programmed cell death protein 1 and vitiligo. 38
31175670 2019
9
Frontal fibrosing alopecia developing on vitiligo. 38
31322136 2019
10
Methylphenidate associated vitiligo in a child: A case report. 38
30821429 2019
11
Skin-resident memory T cells as a potential new therapeutic target in vitiligo and melanoma. 38
31230406 2019
12
Cyclosporine in treatment of progressive vitiligo: An open-label, single-arm interventional study. 38
31389371 2019
13
Genetic and environmental risk factors for vitiligo and melanoma in Pura Raza Español horses. 38
30624804 2019
14
Patient reported outcomes for intensified versus conventional NB-UVB treatment in non-segmental vitiligo. 38
30497304 2019
15
Clinimetric analysis of recently applied quantitative tools in evaluation of vitiligo treatment. 38
30729924 2019
16
Microneedling with Dermaroller 192 needles along with 5-fluorouracil solution in the treatment of stable vitiligo. 38
30654074 2019
17
Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. 38
30945409 2019
18
The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: A population-based retrospective cohort study. 38
30849210 2019
19
Regulatory T-cells in alopecia areata. 38
30989699 2019
20
Platelet-rich plasma and its utility in medical dermatology: A systematic review. 38
31009668 2019
21
Low percentages of regulatory T cells in common variable immunodeficiency (CVID) patients with autoimmune diseases and its association with increased numbers of CD4+CD45RO+ T and CD21low B cells. 38
31103252 2019
22
World Vitiligo Day-A grassroots campaign to improve the quality of life of vitiligo patients. 38
31369192 2019
23
Childhood Vitiligo. 38
30911977 2019
24
Palmoplantar vitiligo: an overlooked entity. 38
30883893 2019
25
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies. 38
30650959 2019
26
The role of long-wavelength ultraviolet A1 (UVA1) in acral vitiligo. 38
30375144 2019
27
T-cell responses against 4-tert-butylphenol-exposed pigmented cells in a patient with occupational vitiligo. 38
30719700 2019
28
Systematic Review of Clinimetric Instruments to determine the severity of Non-segmental Vitiligo. 38
30820942 2019
29
Treatment responses in patients with vitiligo to very potent topical corticosteroids combined with vitaminotherapy in Madagascar. 38
31148154 2019
30
Experimental study and clinical observations of autologous hair follicle cell transplants to treat stable vitiligo. 38
31397397 2019
31
Risk for neurodegenerative disorders in Korean patients with vitiligo: A nationwide retrospective cohort study. 38
30654072 2019
32
A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo. 38
31009664 2019
33
One Stone, Two Birds: Improvement of Early-Onset Vitiligo under Apremilast in a Patient with Plaque Psoriasis. 38
31414705 2019
34
Evidence of a possible therapeutic role of vitamin D in a cohort of adult Caucasian vitiligo patients. 38
31414974 2019
35
The effectiveness of topical calcineurin inhibitors comparing with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis. 38
31408687 2019
36
Is the +405 G/C single nucleotide polymorphism of the vascular endothelial growth factor (VEGF) gene associated with late-onset vitiligo? 38
31135085 2019
37
A comparative study between suction blistering graft, mini punch graft, and hair follicle transplant in treatment of patients with stable vitiligo. 38
30252548 2019
38
Comparison of follicular unit extraction versus plucking of hair follicles as technique of harvesting hair follicles in non-cultured hair follicular cell suspension in vitiligo. 38
31420990 2019
39
Site-oriented depigmentation in vitiligo patients using Q-switched Nd:YAG laser (1,064/532 nm), cryotherapy and chemical peels: A comparative study. 38
31376312 2019
40
Treatment Options for Melanoma of Gray Horses. 38
31279435 2019
41
Ginkgo biloba extract protects human melanocytes from H2 O2 -induced oxidative stress by activating Nrf2. 38
31148371 2019
42
An In-Vitro Assay Estimating Changes in Melanin Content of Melanoma Cells due to Ultra-Dilute, Potentized Preparations. 38
30836409 2019
43
Differentiation of adipose-derived stem cells to functional CD105neg CD73low melanocyte precursors guided by defined culture condition. 38
31399041 2019
44
Ostraceous Psoriasis Presenting as Koebner Phenomenon in a Tattoo 38
31424715 2019
45
Allergic Diseases and Long Term Risk of Autoimmune Disorders: longitudinal cohort study and cluster analysis. 38
31413164 2019
46
A review on traditional uses, phytochemistry and pharmacology of Eclipta prostrata (L.) L. 38
31395303 2019
47
Family Clustering of Autoimmune Vitiligo Results Principally from Polygenic Inheritance of Common Risk Alleles. 38
31327509 2019
48
Body image mediates the impact of pain on depressive symptoms in patients with systemic lupus erythematosus. 38
31369342 2019
49
Single-nucleotide polymorphisms of APE1 associated with risk and prognosis of vitiligo in a Han Chinese population. 38
31430071 2019
50
[Atopic dermatitis and general medical comorbidities]. 38
31240339 2019
Sources

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 KIF1B NM_015074.3(KIF1B): c.4387C> T (p.Arg1463Cys) single nucleotide variant Uncertain significance rs757850683 1:10425479-10425479 1:10365421-10365421

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

74
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601

Sources

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6.
Sources

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
Sources

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
Sources

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....